Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry.
Jung Hee KohYusun LeeWook-Young BaekJinhyun KimKichul ShinPublished in: Therapeutic advances in musculoskeletal disease (2022)
Assessment of sustained remission using the CDAI, SDAI, or Boolean criteria is more stringent, yet congruous with the DAS28-based criteria in RA patients treated with b/tsDMARDs.